Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE. Eikesdal HP, et al. Among authors: leirvaag b. Ann Oncol. 2021 Feb;32(2):240-249. doi: 10.1016/j.annonc.2020.11.009. Epub 2020 Nov 24. Ann Oncol. 2021. PMID: 33242536 Free article. Clinical Trial.
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.
Yndestad S, Engebrethsen C, Herencia-Ropero A, Nikolaienko O, Vintermyr OK, Lillestøl RK, Minsaas L, Leirvaag B, Iversen GT, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Aase HS, Aas T, Gudlaugsson EG, Llop-Guevara A, Serra V, Janssen EAM, Lønning PE, Knappskog S, Eikesdal HP. Yndestad S, et al. Among authors: leirvaag b. JCO Precis Oncol. 2023 Sep;7:e2300338. doi: 10.1200/PO.23.00338. JCO Precis Oncol. 2023. PMID: 38039432 Free PMC article.
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE. Knappskog S, et al. Among authors: leirvaag b. Breast Cancer Res. 2012 Mar 15;14(2):R47. doi: 10.1186/bcr3147. Breast Cancer Res. 2012. PMID: 22420423 Free PMC article. Clinical Trial.
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE. Knappskog S, et al. Among authors: leirvaag b. Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8. Mol Oncol. 2015. PMID: 26004085 Free PMC article.
Prevalence of the CHEK2 R95* germline mutation.
Knappskog S, Leirvaag B, Gansmo LB, Romundstad P, Hveem K, Vatten L, Lønning PE. Knappskog S, et al. Among authors: leirvaag b. Hered Cancer Clin Pract. 2016 Sep 27;14:19. doi: 10.1186/s13053-016-0059-0. eCollection 2016. Hered Cancer Clin Pract. 2016. PMID: 27708748 Free PMC article.